Minerva Neurosciences Announces Financing of up to $200 Million, Led by Vivo Capital, to Advance Its Schizophrenia Drug Roluperidone.
Amount Raised
$200 Million
Round Type
Funding Round
WalthamBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmapharmaceuticalsInvestors
Description
Minerva Neurosciences announced a private placement agreement with institutional investors to raise up to $200 million. An initial $80 million is provided upfront via a new Series A preferred stock issuance, with an additional $120 million contingent on future milestones. The financing is led by Vivo Capital alongside other notable healthcare-focused funds. Proceeds will support a Phase 3 trial of roluperidone and the resubmission of its NDA to the FDA.
Who to call at Minerva Neurosciences, and when
A new round usually means Minerva Neurosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Minerva Neurosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Minerva Neurosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Minerva Neurosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Minerva Neurosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Minerva Neurosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.